CatalYm Raises $150 Million in Funding for Cancer Immunotherapy Expansion

CatalYm raises $150M in Series D Funding

CatalYm (Linkedin), a Munich-based immune therapy solutions provider for solid tumors, has secured $150M in Series D funding. With a focus on advancing their Phase 2b development of visugromab, a potential cancer immunotherapy, CatalYm aims to collaborate with oncology treatment centers and pharmaceutical companies to revolutionize cancer treatment.

Funding Amount: $150 million

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Phil L'Huillier (CEO Linkedin)

What CatalYm needs to buy: CatalYm is seeking partnerships with clinical research organizations, manufacturers, and regulatory consultants to support their Phase 2b studies, ensure efficient production and distribution of their immune therapy solutions, and navigate the complex landscape of cancer immunotherapy regulations. Companies specializing in clinical trial services, manufacturing, and regulatory expertise are ideal partners for CatalYm's ambitious expansion plans.